Health Care International - Genaera Corporation Presents Additional Promising Preclinical Type 2 Diabetes Data For Trodusquemine (MSI-1436) At American Diabetes Association
Genaera Corporation (Nasdaq: GENR) announced a presentation by Genaera scientists of preclinical data on trodusquemine (MSI-1436), Genaera's lead drug candidate for the treatment of type 2 diabetes and obesity, during the 68th Scientific Sessions o
Comments